Nonsecretory Multiple Myeloma: Options in Assessment and Treatment

MARCH 27, 2017
UPCOMING /Recent Talks

Nonsecretory Multiple Myeloma: Options in Assessment and Treatment

with Dr. Frits Van Rhee
March 27th, 2017. 5PM EST RSVP
Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component parts into either the blood or urine, hence called non-secretory myeloma. Some non-secretory myeloma patients may produce the immunoglobulin proteins but they have defects in secretion. Due to lack of these protein biomarkers in blood and urine, it may be difficult to assess and treat the disease. Our myeloma panel is talking to Dr. Frits Van Rhee about latest developments and new options available in assessment and treatment of nonsecretory myeloma.
Panelists
Dr. Frits Van Rhee
Gary Petersen
Jack Aiello
Yelak Biru
Priya Menon
Developments in Personalized Medicine and New Options in Breast Cancer Treatment 
with Dr. Jame Abraham 
March 30th, 2017. 5PM EST RSVP
 In this era of personalized medicine the standard “one dose fits all” approach to cancer care has been ineffective leading to treatment failures. Personalized medicine is a new healthcare paradigm that allows physicians to choose treatment methodology optimally based on a person’s genetic or protein profiles. Our breast cancer panel is talking to Dr. Jame Abraham of Cleveland Clinic to learn about the developments in personalized medicine in breast cancer treatment. The panel will also discuss research in this field and new options available for breast cancer treatment.
Panelists
Dr. Jame Abraham
Beverly McKee 
Terry Arnold
Heidi Floyd
Shweta Mishra

High Risk Myeloma Treatment Options

with Dr. Robert Orlowski
February 24th, 2017. 5PM EST LISTEN
Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. Despite many new drugs and drug combinations being approved, long term benefits for high risk multiple myeloma patients is less clear. We continue our discussion on high risk myeloma with Dr. Robert Orlowski and talk about the treatment options that are available for a high risk patient. Panelists
Dr. Robert Orlowski
Gary Petersen
Cynthia Chmielewski
Yelak Biru
Priya Menon
For any of the talks dial-in to 718-664-6574 to participate and ask a question LIVE On-Air! Only 50 callers permitted at one time so HURRY!
Our Picks
Categories:
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
0
20977